SEE MORE: Clinton Delivers Poison Pill To Biotech ETFs
Eddy Elfenbein, editor of the Crossing Wall Street blog, told CNBC he likes IBB as a post-Election Day idea “because he likes the valuations in biotech right now, and he predicts actually regulating drug pricing and passing legislation, as opposed to simply speaking about it during the campaign season, is much more difficult.”
Biotech’s struggles this year against a hostile political backdrop have given the historically richly valued sector some of its most attractive valuations in recent memory.
For more information on the biotech sector, visit our biotechnology category.
iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB)
